D1、D2和D3结构域缺失的重组鞭毛蛋白作为新型免疫佐剂的特性研究
本研究开发了缺失全部D2、D3及部分D1结构域的重组鞭毛蛋白,评估其结构稳定性、体外TLR5激活能力及小鼠鼻内给药后的体内固有免疫应答和针对卵清蛋白的抗体应答。结果显示多数重组分子保留α螺旋结构,体内TLR5依赖的固有免疫应答与天然鞭毛蛋白相当,且可作为呼吸道佐剂,但内在抗原性降低。
要点
- 重组鞭毛蛋白缺失D2、D3及部分D1后仍保留α螺旋结构和热稳定性。
- 鼻内给予2 μg重组鞭毛蛋白可诱导与天然蛋白等效的小鼠TLR5依赖固有免疫应答。
- 重组鞭毛蛋白可作为呼吸道佐剂增强对卵清蛋白的抗体应答,但内在抗原性降低。
核心结论
- 在FliCΔ174-400基础上进一步缺失D2和D1远端不影响抗原性,也不显著改变免疫刺激佐剂活性。
- 研究生成了一套新型重组鞭毛蛋白,可作为TLR5依赖的候选疫苗佐剂。
研究设计与样本
- 研究开发了多种重组鞭毛蛋白,缺失全部D2、D3及部分D1结构域。
- 体外评估TLR5激活能力,小鼠鼻内给予2 μg鞭毛蛋白后评估体内TLR5依赖的固有免疫应答。
- 评估重组鞭毛蛋白作为呼吸道佐剂对卵清蛋白抗体应答的佐剂效果。
主要发现
- 多数重组分子保留与天然蛋白一样抗热变性的α螺旋二级结构。
- 重组鞭毛蛋白体外触发TLR5的能力差异显著,但小鼠鼻内给予2 μg后多数诱导等效的体内TLR5依赖固有免疫应答。
- 重组鞭毛蛋白可作为呼吸道佐剂 eliciting 对卵清蛋白的抗体应答,但其内在抗原性较天然鞭毛蛋白降低,且与FliCΔ174-400相比未增加。
临床怎么用
- 重组鞭毛蛋白可作为TLR5依赖的候选黏膜佐剂用于疫苗开发。
- 鼻内给药2 μg重组鞭毛蛋白可诱导小鼠固有免疫应答,支持其呼吸道佐剂用途。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bacterial flagellin activates the innate immune system and ultimately the adaptive immune system through a Toll-like receptor 5 (TLR5)-dependent signaling mechanism. Given that TLR5 is widely distributed in epithelia, flagellin is currently being developed as a mucosal adjuvant. Flagellin FliC from Salmonella enterica has four domains: the conserved D0 and D1 domains and the hypervariable D2 and D3 domains. The deletion of D3 and partial deletion of D2 in the recombinant FliCΔ174-400 strongly impairs flagellin's intrinsic antigenicity but does not affect the TLR5-dependent immunostimulation activity, i.e., the capacity to promote innate responses and adaptive responses to co-administered antigens. Here, we describe the development of novel recombinant flagellins with various deletions encompassing all of D2 and D3, and part of D1. Most of the recombinant molecules conserved an α-helical secondary structure that was as resistant to heat denaturation as the native protein. Whereas the recombinant flagellins' ability to trigger TLR5 varied markedly in vitro, most gave equivalent in vivo TLR5-dependent innate immune responses following intranasal administration of 2 μg of flagellin to mice. Concordantly, the recombinant flagellins were also valuable respiratory adjuvants for eliciting antibody responses to the foreign antigen ovalbumin, although their intrinsic antigenicity was decreased compared to the native flagellin and not increased compared to FliCΔ174-400. Our results show that the additional deletions of D2 and the distal part of D1 of FliCΔ174-400 does not impact on antigenicity and does not significantly modify the immunostimulatory adjuvant activity. Altogether, this study generated a novel set of recombinant flagellin that constitutes a portfolio of TLR5-dependent candidate adjuvants for vaccination.
引用
- Biedma ME, Cayet D, Tabareau J, et al. Recombinant flagellins with deletions in domains D1, D2, and D3: Characterization as novel immunoadjuvants. Vaccine. 2018. PMID: 30583910. doi:10.1016/j.vaccine.2018.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。